Hussein Arkhagha - Hikma Pharmaceuticals General Counsel
| HKMPF Stock | USD 22.33 1.92 7.92% |
Executive
Mr. Hussein Arkhagha is General Counsel of Hikma Pharmaceuticals Plc. Hussein has Group level responsibility for legal, regulatory and taxation related matters. During 17 years at Hikma, Hussein has held several legal leadership roles, including heading legal in MENA, the shareholders department and tax. Qualified lawyer in Jordan. Masters degree in International Business Law from the University of Manchester, under a UK Chevening Scholarship. since 2013.
| Tenure | 11 years |
| Phone | 44 20 7399 2760 |
| Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Francisco Mangual | cbdMD Inc | 45 | |
| Nareg Sagherian | Evolus Inc | N/A | |
| Rui Avelar | Evolus Inc | 56 | |
| Alycia Torres | Biofrontera | N/A | |
| Daniel JD | Biofrontera | N/A | |
| Brian Johnston | Evolus Inc | N/A | |
| Tomoko YamagishiDressler | Evolus Inc | N/A | |
| Lisa Wilson | Eagle Pharmaceuticals | N/A | |
| Jessica Novak | Evolus Inc | N/A | |
| Zeb Booker | cbdMD Inc | N/A | |
| Paul Bruinenberg | Eagle Pharmaceuticals | 53 | |
| Jeffrey Plumer | Evolus Inc | N/A | |
| Bradley Whitford | cbdMD Inc | 43 | |
| Shannon Charles | cbdMD Inc | N/A | |
| David Johnson | cbdMD Inc | 54 | |
| Lance Blundell | cbdMD Inc | 53 | |
| Michael Jafar | Evolus Inc | 37 | |
| Valentin MD | Eagle Pharmaceuticals | N/A | |
| Samantha Widdicombe | Biofrontera | N/A | |
| Steven Krill | Eagle Pharmaceuticals | 56 | |
| Reed McClung | Eagle Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
| Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
| Khalid Nabilsi, Chief Officer | ||
| Hussein Arkhagha, General Counsel | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Pamela Kirby, Non-Executive Independent Director | ||
| John Castellani, Non-Executive Independent Director | ||
| Brian Hoffman, President and Chief Executive of - Generics Division | ||
| Ali AlHusry, Non-Executive Director | ||
| Jochen Gann, Non-Executive Director | ||
| Engineer Darwazah, Ex CEO | ||
| Peter Speirs, Company Secretary | ||
| Patrick Butler, Non-Executive Independent Director | ||
| Brian Hoffmann, Pres Generics | ||
| Said Darwazah, Chairman and CEO | ||
| Michael Raya, President and CEO, USA | ||
| Samuel Park, Global US | ||
| Ronald Goode, Non-Executive Independent Director | ||
| Bryan Hotston, CIO | ||
| Sigurdur Olafsson, CEO | ||
| Breffni Byrne, Non-Executive Independent Director | ||
| Nina Henderson, Non-Executive Independent Director | ||
| Cynthia Schwalm, Independent Non-Executive Director | ||
| Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
| Michael Ashton, Non-Executive Independent Director | ||
| Majda Labadi, Corporate Vice President - Human Resources | ||
| Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Robert Pickering, Senior Non-Executive Independent Director | ||
| Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
| CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Shares Owned By Insiders | 29.67 % | |||
| Shares Owned By Institutions | 41.69 % | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |